Letters to the Editor
Early Access
Erythema nodosum-like panniculitis during BRAF inhibitor therapy for melanoma: never forget latent tuberculosis infection
Publisher's note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article or claim that may be made by its manufacturer is not guaranteed or endorsed by the publisher.
Published: 4 June 2026
28
Views
10
Downloads
Authors
Dear Editor,
Targeted therapies for melanoma play a pivotal role in the management of patients with advanced BRAF-mutated disease. Despite their efficacy, these treatments are associated with a spectrum of adverse events, particularly cutaneous toxicities, including photo-aggravated eruptions, increased risk of non-melanoma skin cancers, and other less frequent manifestations. Herein, we describe a clinical case and briefly review a rare and likely under-recognized adverse event: erythema nodosum (EN)-like panniculitis during BRAF inhibitor therapy. [...]
Downloads
Download data is not yet available.
Citations
1. Lantto R, Jokelainen J, Huilaja L, Sinikumpu SP. Erythema nodosum in northern Finland between 1996 and 2019: A register-based study. J Dermatol 2024;51:1017-21.
2. Bardazzi F, Loi C, Clarizio G, et al. Erythema nodosum: a clinical manifestation of Neisseria gonorrhoeae infection. Int J Dermatol 2022;61:e306-7.
3. Maglie R, Genovese G, Solimani F, et al. Immune-Mediated Dermatoses in Patients with Haematological Malignancies: A Comprehensive Review. Am J Clin Dermatol 2020;21:833-54.
4. Mössner R, Zimmer L, Berking C, et al. Erythema nodosum-like lesions during BRAF inhibitor therapy: Report on 16 new cases and review of the literature. J Eur Acad Dermatol Venereol 2015;29:1797-806.
5. Kye Y, Zhao G, Guhan S, et al. Research letter: BRAF-inhibitor induced panniculitis - A systematic review. J Am Acad Dermatol 2024;90:420-3.
6. Requena L, Yus ES. Panniculitis. Part I. Mostly septal panniculitis. J Am Acad Dermatol 2001;45:163-83.
7. Boonchai W, Suthipinittharm P, Mahaisavariya P. Panniculitis in tuberculosis: a clinicopathologic study of nodular panniculitis associated with tuberculosis. Int J Dermatol 1998;37:361-3.
8. Kim KS, Kim JS, Kim SS, Kim CW. Association between erythema nodosum/erythema induratum of Bazin and Mycobacterium tuberculosis infection in Koreans. Indian J Dermatol Venereol Leprol 2021;1-5.
9. Seban RD, Vermersch C, Champion L, et al. Immune-Related Erythema Nodosum Mimicking in Transit Melanoma Metastasis on [18F]-FDG PET/CT. Diagnostics 2021;11:747.
10. Ben-Betzalel G, Baruch EN, Boursi B, et al. Possible immune adverse events as predictors of durable response to BRAF inhibitors in patients with BRAF V600-mutant metastatic melanoma. Eur J Cancer Oxf Engl 1990 2018;101:229-35.
How to Cite
1.
Guglielmo A, D'Alì L, Deotto ML, Cimadamore A, Pascoletti G, Poletto E, et al. Erythema nodosum-like panniculitis during BRAF inhibitor therapy for melanoma: never forget latent tuberculosis infection. Dermatol Reports [Internet]. 2026 Jun. 4 [cited 2026 Jun. 8];. Available from: https://journals.pagepress.net/dr/article/view/10380
Copyright (c) 2026 the Author(s)
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
